Ethyl 3-Amino-1H-Pyrrole-2-Carboxylate Hydrochloride

Ethyl 3-amino-1H-pyrrole-2-carboxylate hydrochloride appears as a white to off-white crystalline powder, cataloged by major research chemical suppliers under product codes specific to their inventory but sharing a consistent structural identity: the ethyl ester of 3-amino-1H-pyrrole-2-carboxylic acid in its HCl salt form. The material’s utility as a heterocyclic building block is firmly anchored in the juxtaposition of an amino group at the 3‑position and an activated ester at the 2‑position, a substitution pattern that enables regioselective annulations toward pyrrolo[3,2‑d]pyrimidines, pyrrolo[3,2‑b]pyridines, and related fused systems recurrent in kinase inhibitor scaffolds. A typical certificate of analysis assigns an HPLC purity of ≥ 97.0 % (area‑%, reverse‑phase C18 column, gradient of 0.1 % trifluoroacetic acid in water/acetonitrile, UV detection at 254 nm), supported by identity confirmation through 1H NMR (400 MHz, DMSO‑d₆) and 13C NMR. Residual solvents are monitored by static headspace GC‑FID following the approach of USP <467>, and heavy metals fall below 10 ppm when assayed by ICP‑MS as per USP <233>. The hydrochloride moiety not only simplifies isolation as a stable crystalline solid but also modifies the solubility profile compared to the free‑base analog: solubility in dimethylformamide and dimethyl sulfoxide exceeds 50 mg·mL⁻¹, methanol solubility sits near 25 mg·mL⁻¹, while aqueous solubility remains limited (< 5 mg·mL⁻¹) at 25 °C, a behavior that dictates solvent selection in nucleophilic substitution and palladium‑catalyzed coupling steps.

The most immediate operational distinction lies in physical form: the free base of ethyl 3‑amino‑1H‑pyrrole‑2‑carboxylate is an oil or low‑melting solid at ambient temperature, prone to oxidative discoloration upon prolonged exposure to air, whereas the hydrochloride salt is a free‑flowing powder with a decomposition point exceeding 180 °C, permitting accurate weighing under standard laboratory conditions without cold‑storage withdrawal. This phase difference directly affects process mass intensity in parallel synthesis campaigns where dozens of amide couplings or SNAr reactions are run in array format; solid dosing via automated powder dispensers on platforms such as the Chemspeed SWING loses accuracy when resins or oils are involved. Beyond handling, the protonation state of the pyrrole nitrogen and the amino group in the HCl salt can suppress undesired side reactions during amide bond formation. For instance, activation of the carboxylate after ester hydrolysis to the corresponding acid generates the acid chloride or mixed anhydride; the presence of the hydrochloride counterion retards intramolecular nucleophilic attack by the 3‑amino functionality, reducing diketopiperazine‑type cyclization that depletes the reactive intermediate.

The table below summarizes key parameters for the ethyl ester hydrochloride and three structurally adjacent analogs often considered during route scouting. Variations in the ester alcohol and salt form alter not only melting range and solubility but also the steric and electronic environment of the carboxyl electrophile, which in turn dictates coupling efficiency and protecting group strategy. All data were collected on lots produced in 200 L glass‑lined reactors under ISO 7 cleanroom conditions, purified by recrystallization from ethanol/water (3:1 v/v) or by normal‑phase flash chromatography on silica gel (particle size 40–63 µm).

The free base shows a markedly greater downfield shift window for the pyrrole H‑5 proton because of the altered electron density distribution in the neutral ring, and its purity ceiling is constrained by oxidative oligomerization during storage. The methyl ester hydrochloride offers a faster hydrolysis rate in alkaline media (complete saponification in 1 M NaOH/THF at 0 °C within 15 min versus 45 min for the ethyl ester), making it suitable when the carboxylic acid must be liberated without heating. Conversely, the tert‑butyl ester hydrochloride is cleaved under acidic conditions (trifluoroacetic acid/CH₂Cl₂ 1:1, 2 h, rt), leaving the amino group protonated, which can be advantageous for subsequent solid‑phase extraction workup.

In routes that depend on Suzuki, Sonogashira, or Buchwald‑Hartwig chemistry at the C‑4 or C‑5 position of the pyrrole, the amino group requires protection before halogenation, and the choice of ester influences the compatibility of the overall protecting‑group regime. Halogenation of ethyl 3‑amino‑1H‑pyrrole‑2‑carboxylate hydrochloride with N‑bromosuccinimide in DMF at −10 °C delivers the 4‑bromo derivative in 75–82 % isolated yield, as verified on a 1 kg pilot batch processed in a 30 L jacketed glass reactor with retreat‑curve impeller agitation at 200 rpm. Without the HCl salt, the free base generates a complex mixture containing the 3,4,5‑tribromo byproduct, with the desired monobromide yield dropping below 40 %; protonation of the ring nitrogen attenuates its activating effect and steers electrophilic substitution to the less‑hindered 4‑position. The ester’s steric demand further modulates regioselectivity. When the tert‑butyl ester is employed under identical conditions, the 4‑bromo/5‑bromo ratio shifts from 9:1 to 6:1 due to increased steric shielding at the ester‑adjacent 3‑amino group, which slows the attack at C‑4 relative to C‑5. These data, acquired by LC‑MS monitoring (electrospray positive mode, cone voltage 30 V), are consistent with published Hammett correlations for substituted pyrroles.

A further layer of complexity arises in large‑scale Sonogashira alkynylation of the 4‑bromo intermediate. Using Pd(PPh₃)₂Cl₂ (2 mol %) and CuI (4 mol %) in triethylamine/DMF (1:4) at 60 °C, complete conversion of the ethyl ester·HCl‑derived bromide is achieved within 3 h, whereas the corresponding methyl ester consumes more than 6 h to reach 95 % conversion under otherwise identical conditions. The rate discrepancy is attributed to the ethyl ester’s marginally higher electron‑withdrawing character, which increases the electrophilicity of the adjacent C‑4‑Br center. For process chemists scaling a kinase inhibitor intermediate, the difference translates into a solvent‑exchange step before final cyclization, as the ethyl ester’s slower hydrolysis in the subsequent pyrimidine ring closure may require a higher temperature or longer residence time in continuous flow—variables that must be balanced against thermal stability limits of the acetylene coupling partner.

The ethyl 3‑amino‑1H‑pyrrole‑2‑carboxylate hydrochloride scaffold is most frequently advanced through a three‑step sequence: (i) N‑alkylation or N‑arylation of the pyrrole nitrogen, (ii) ester hydrolysis to the carboxylic acid, and (iii) cyclodehydration with an amidine or orthoformate equivalent to construct a fused pyrimidine ring. In the preparation of 7H‑pyrrolo[3,2‑d]pyrimidin‑4‑amine derivatives—common hinge‑binding motifs in Janus kinase and Aurora kinase programs—the 2‑carboxylic acid obtained from saponification of the ethyl ester hydrochloride is activated with carbonyldiimidazole (CDI) in DMF and then treated with formamidine acetate at 80 °C for 16 h. The crude pyrimidinone is chlorinated with POCl₃ in acetonitrile at 90 °C, and the resulting 4‑chloropyrrolopyrimidine is subjected to SNAr with a substituted aniline. Yields over this telescoped sequence routinely fall in the 45–55 % range when starting from the HCl salt, compared with 28–36 % for the free base, a gap principally attributable to cleaner N‑alkylation in the first step, where the hydrochloride suppresses competing alkylation at the 3‑amino group. Pyrogenicity data from differential scanning calorimetry (DSC, ramp 10 °C·min⁻¹ under nitrogen) of the CDI‑activation intermediate reveal an exotherm onset at 142 °C with an energy release of −420 J·g⁻¹, mandating active cooling and slow reagent dosing for any batch exceeding 100 g.

An alternative cyclization pathway relies on the ethyl ester directly without hydrolysis. Heating the N‑protected amino‑ester with formamide in the presence of ammonium chloride at 160 °C in a pressure tube affords the pyrimidinone in one pot, albeit with formation of 3–5 % of a regioisomeric pyrrolo[3,4‑d]pyrimidine byproduct that co‑crystallizes and requires fractional crystallization from isopropanol/water (85 °C to 5 °C over 8 h). The ethyl ester hydrochloride’s lower solubility in hot isopropanol relative to the undesired isomer facilitates a higher recovery yield (72 %) of the desired product with 98.5 % purity, compared with the methyl ester analog which partitions less cleanly.

The hydrochloride salt is hygroscopic at relative humidity above 60 %; exposure to ambient air for more than 4 hours in an uncontrolled laboratory (average 25 °C, 55 % RH) increases the water content by Karl Fischer titration from < 0.3 % to 1.8 %. For synthetic operations where stoichiometry must be maintained within ± 2 mol %, the material should be dispensed from a container equilibrated in a glovebox purged with dry nitrogen (dew point < −40 °C) or used immediately after removal from a sealed, desiccated package. Long‑term storage mandates storage at 2–8 °C under argon in amber glass vials fitted with PTFE‑lined caps; under these conditions, the chromatographic purity drifts less than 0.2 % over 24 months, as tracked by stability studies conducted according to ICH Q1A(R2) guidelines.

Incompatibility arises with strong aqueous alkalis (> 0.5 M NaOH) even at 0 °C, where ester hydrolysis is accompanied by rapid elimination of ammonia from the 3‑amino group and pyrrole ring degradation, evidenced by a color change to dark brown within 10 min. Furthermore, premixing with primary amine nucleophiles in aprotic solvents without a hindered base such as N,N‑diisopropylethylamine can trigger slow ester aminolysis, generating an ethyl‑amidine adduct that complicates purification. On production lines equipped with Hastelloy C‑22 reactors, a pH excursion below 2.0 during acidic workup after a Pd‑coupling step has been observed to cause partial de‑esterification (6–8 % free acid) over 2 h at 50 °C, requiring a pH adjustment and an additional extraction cycle. The operating window for aqueous workup is therefore maintained between pH 4.0 and 6.5, achieved by buffering with 0.1 M citrate.

This product is manufactured under a quality management system aligned with ISO 9001:2015 and is typically accompanied by a certificate of analysis referencing at minimum HPLC purity, residual solvent profile (USP <467> Class 3 limits), and heavy metals by USP <233>. Batches intended for early‑phase pharmaceutical development may be produced in non‑GMP kilo‑lab settings, but any lot progressing into GLP toxicology or Phase I clinical supply is transferred to a GMP‑compliant campaign where the master batch record specifies a reaction calorimetry study on the halogenation and CDI‑activation steps per RC1e protocol. The ethyl 3‑amino‑1H‑pyrrole‑2‑carboxylate hydrochloride is not a pharmacopeial monograph material, and its specifications are defined by the end user’s TPP (target product profile) for the downstream API intermediate. In the European supply chain, a REACH pre‑registration inquiry is addressed on a case‑by‑case basis through an Only Representative, and the substance is routinely shipped under a Safety Data Sheet classifying the product as a non‑dangerous good for transport under ADR/RID/IMDG code, provided it is packaged in fiberboard drums with inner LDPE liners at a fill weight not exceeding 25 kg.

Comparison with the free base and with the methyl ester hydrochloride reveals a differentiated product profile tailored to routes where air‑stable solid handling, a linear solubility gradient in polar aprotic media, and predictable regioselectivity in electrophilic halogenation are paramount. The ethyl ester occupies a midpoint of hydrolytic lability between the methyl and tert‑butyl esters, providing the synthetic flexibility to deploy either acidic or basic deprotection protocols without committing the entire route to a single protecting‑group philosophy. Where a manufacturing campaign requires simultaneous delivery of the carboxylic acid for an active ester coupling and the intact ester for a convergent late‑stage cyclization, storing and dispensing both the hydrochloride salt and the hydrolyzed acid from the same precursor lot minimizes macro‑impurity fingerprint divergence, a practice verified by LC‑MS trace analysis across three consecutive 100 kg campaigns of a pyrrolopyrimidine‑based drug candidate.